Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 10/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.40 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.40 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22424970 | 1.00 | SSTR4 (0.47) | SSTR4IDO1DRD2DRD3TACR3 | |
| SCHEMBL21146060 | 0.79 | CAMKK1 (0.48) | IDO1DRD2DRD3SLC22A12CAMKK1 | |
| SCHEMBL21289832 | 0.79 | CAMKK1 (0.48) | IDO1DRD2DRD3SLC22A12CAMKK1 | |
| SCHEMBL28431268 | 0.79 | CAMKK1 (0.48) | IDO1DRD2DRD3SLC22A12CAMKK1 | |
| SCHEMBL22424992 | 0.79 | CAMKK1 (0.48) | IDO1DRD2DRD3SLC22A12CAMKK1 | |
| SCHEMBL8097215 | 0.79 | SSTR4 (0.60) | SSTR4SMN1; SMN2MAPT | |
| SCHEMBL21146596 | 0.78 | ALDH1A1 (0.56) | DRD2DRD3MAPT | |
| SCHEMBL21146595 | 0.78 | ALDH1A1 (0.56) | DRD2DRD3MAPT | |
| SCHEMBL21052508 | 0.78 | IDO1 (0.43) | SSTR4IDO1DRD2DRD3SLC22A12 | |
| SCHEMBL21052509 | 0.78 | IDO1 (0.43) | SSTR4IDO1DRD2DRD3SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291008-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| WO-2019111107-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291008-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | SSTR4 4242/4885IDO1 1/4885DRD2 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.